N Dunkel
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2018
09.01.2018Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
09.01.2018Br J Cancer 2018
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Ben Aissa A, Dietrich P-Y
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Hottinger A, Bodmer A, Weber D, Schaller K, Mach N, Hundsberger T, Vargas M, Dunkel N, Squiban D, Espeli V, Aissa A, Dietrich P. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. Br J Cancer 2014; 110:2655-2661.
01.05.2014Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
01.05.2014Br J Cancer 2014; 110:2655-2661
Hottinger A F, Bodmer A, Weber D C, Schaller K, Mach N, Hundsberger Thomas, Vargas M I, Dunkel N, Squiban D, Espeli V, Aissa A B, Dietrich P-Y